Operose Advisors’s BioLife Solutions BLFS Stock Holding History

Operose Advisors’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-518	Closed	-$7.15K	–	622
2023 Q3	$7.15K	Buy	+518	New	+$8.16K	﹤0.01%	622

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Operose Advisors's BLFS Position: Q4 2023 in Review

Operose Advisors sold out of BioLife Solutions (BLFS) in Q4 2023, closing a stake of 518 shares — an estimated $7.15K sold.

Operose Advisors first reported a position in BLFS in Q3 2023 and held it in 1 quarter. The position peaked at $7.15K in Q3 2023. 140 funds tracked by Wall St. Rank hold BLFS as of Q4 2023.

Operose Advisors reported no remaining BioLife Solutions position as of Q4 2023 after selling out during the quarter.
Operose Advisors sold 518 BioLife Solutions shares in Q4 2023, an estimated $7.15K.
Operose Advisors first reported a position in BioLife Solutions in Q3 2023 and held it in 1 quarter.
Operose Advisors's BioLife Solutions position peaked at $7.15K in Q3 2023.
140 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2023.

Based on Operose Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.